Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
T Kato, I Casarini, M Cobo, C Faivre-Finn… - Lung Cancer, 2024 - Elsevier
Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …
patients with unresectable stage III non-small cell lung cancer (NSCLC). The current …
Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review
B Allignet, D De Ruysscher, I Martel-Lafay… - Cancer Treatment …, 2023 - Elsevier
In unresectable stage III non-small cell lung cancer (NSCLC), the standard of care for most fit
patients is concurrent chemotherapy with normofractionated radiotherapy (NFRT), followed …
patients is concurrent chemotherapy with normofractionated radiotherapy (NFRT), followed …
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review …
T Liu, S Li, S Ding, J Qiu, C Ren, J Chen, H Wang… - …, 2023 - thelancet.com
Background Pneumonitis is a common complication for patients with locally advanced non-
small cell lung cancer undergoing definitive chemoradiotherapy (CRT). It remains unclear …
small cell lung cancer undergoing definitive chemoradiotherapy (CRT). It remains unclear …
Clinical implications of the serum platelet-to-lymphocyte ratio in the modern radiation oncology era: research update and literature review
DS Lee - Radiation Oncology, 2024 - Springer
Radiation therapy (RT) continues to be the primary approach for treating cancer, and
numerous cancer biomarkers associated with oncological outcomes have been investigated …
numerous cancer biomarkers associated with oncological outcomes have been investigated …
International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer
Importance Standard of care for unresectable locally advanced non–small cell lung cancer
(NSCLC) involves definitive chemoradiotherapy followed by maintenance therapy with …
(NSCLC) involves definitive chemoradiotherapy followed by maintenance therapy with …
Management of oncogene driven locally advanced unresectable non-small cell lung cancer
J Loh, JL Low, M Sachdeva, PQJ Low… - Expert Review of …, 2023 - Taylor & Francis
Introduction The current standard of care of locally advanced non-small cell lung cancer (LA-
NSCLC) is concurrent chemoradiation, followed by consolidation durvalumab. However …
NSCLC) is concurrent chemoradiation, followed by consolidation durvalumab. However …
Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: A systematic review and meta …
C Han, J Qiu, L Bai, T Liu, J Chen, H Wang… - International Journal of …, 2024 - Elsevier
Purpose Chemoradiotherapy (CRT) combined with immune checkpoint inhibitors (ICIs) is
the standard of care for patients with unresectable and locally advanced non-small cell lung …
the standard of care for patients with unresectable and locally advanced non-small cell lung …
Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer
A Sugimoto, H Kaneda, N Yoshimoto, K Nagata… - Scientific Reports, 2024 - nature.com
The usefulness of the derived neutrophil-to-lymphocyte ratio (dNLR) and its dynamics
before/after durvalumab consolidation therapy to predict safety or efficacy remains unclear …
before/after durvalumab consolidation therapy to predict safety or efficacy remains unclear …
Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results
MV Verschueren, T Dijs, JL Gulikers, A Veelen… - …, 2023 - Taylor & Francis
Aim: We investigated the effectiveness of durvalumab post-concurrent CRT (cCRT) and post-
sequential CRT (sCRT) versus cCRT and sCRT alone and compared these outcomes with …
sequential CRT (sCRT) versus cCRT and sCRT alone and compared these outcomes with …
A propensity-matched retrospective comparative study with historical control to determine the real-world effectiveness of durvalumab after concurrent …
CK Park, N Jeon, HK Park, HJ Oh, YC Kim, HL Jeon… - Cancers, 2023 - mdpi.com
Simple Summary The PACIFIC trial demonstrated the survival benefits of durvalumab
consolidation (DC) in patients with unresectable stage III non–small cell lung cancer …
consolidation (DC) in patients with unresectable stage III non–small cell lung cancer …